Lucy Scientific Discovery (Lucy Scientific Discovery) Debt-to-Equity : 27.32 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery Debt-to-Equity?

Lucy Scientific Discovery's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.49 Mil. Lucy Scientific Discovery's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.72 Mil. Lucy Scientific Discovery's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0.08 Mil. Lucy Scientific Discovery's debt to equity for the quarter that ended in Dec. 2023 was 27.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lucy Scientific Discovery's Debt-to-Equity or its related term are showing as below:

LSDI' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.07 Med: -0.02 Max: 27.32
Current: 27.32

During the past 3 years, the highest Debt-to-Equity Ratio of Lucy Scientific Discovery was 27.32. The lowest was -1.07. And the median was -0.02.

LSDI's Debt-to-Equity is ranked worse than
99.76% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs LSDI: 27.32

Lucy Scientific Discovery Debt-to-Equity Historical Data

The historical data trend for Lucy Scientific Discovery's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery Debt-to-Equity Chart

Lucy Scientific Discovery Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Equity

-0.35

-1.01

0.38

Lucy Scientific Discovery Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						-0.93	0.30	0.38	0.64	27.32

Competitive Comparison of Lucy Scientific Discovery's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucy Scientific Discovery's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's Debt-to-Equity falls into.

Lucy Scientific Discovery Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lucy Scientific Discovery's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.399	+	1.39)	/	4.679
	=	0.38

Lucy Scientific Discovery's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.494	+	0.719)	/	0.081
	=	27.32

Lucy Scientific Discovery (NAS:LSDI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lucy Scientific Discovery Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6

Website

https://www.lucyscientific.com

Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.

Executives

Richard D Nanula	director, officer: Executive Chairman	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko	officer: Chief Financial Officer	C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany	director, officer: President and CEO	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy	officer: Chief Scientific Officer	C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6